{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:30:33Z","timestamp":1791873033608,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.04.067","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T18:53:12Z","timestamp":1588791192000},"page":"4405-4411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: A Phase III randomized study"],"prefix":"10.1016","volume":"38","author":[{"given":"Alejandra","family":"Esteves-Jaramillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jeanfreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neveu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Singh Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.04.067_b0005","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.067_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2020.04.067_b0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/hv.22302","article-title":"The changing epidemiology of meningococcal disease in North America 1945\u20132010","volume":"9","author":"Baccarini","year":"2013","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.vaccine.2020.04.067_b0020","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current Epidemiology and Trends in Meningococcal Disease-United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0025","unstructured":"Centers for Disease Control and Prevention. Age as a Risk Factor. Atlanta; 2017."},{"key":"10.1016\/j.vaccine.2020.04.067_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12879-018-3598-3","article-title":"Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: a cross-sectional study","volume":"19","author":"Miglietta","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0035","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.33321\/cdi.2016.40.50","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2020.04.067_b0040","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.067_b0045","first-page":"4","article-title":"Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012","volume":"4","author":"Gunaratnam","year":"2013","journal-title":"Western Pac Surveill Response J"},{"key":"10.1016\/j.vaccine.2020.04.067_b0050","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1186\/s12979-017-0107-2","article-title":"Vaccines for the elderly: current use and future challenges","volume":"15","author":"Weinberger","year":"2018","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2020.04.067_b0055","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.23.1900070","article-title":"Suspected cluster of Neisseria meningitidis W invasive disease in an elderly care home: do new laboratory methods aid public health action? United Kingdom, 2015","volume":"24","author":"Lawler","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.04.067_b0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.04.067_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tmaid.2018.05.003","article-title":"The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review","volume":"24","author":"Yezli","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.26719\/2013.19.4.389","article-title":"Consensus recommendation for meningococcal disease prevention for Hajj and Umra pilgrimage\/travel medicine","volume":"19","author":"Shibl","year":"2013","journal-title":"East Mediterr Health J"},{"key":"10.1016\/j.vaccine.2020.04.067_b0075","doi-asserted-by":"crossref","unstructured":"Funk A, Uadiale K, Kamau C, Caugant DA, Ango U, Greig J. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Curr. 2014;6.","DOI":"10.1371\/currents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518"},{"key":"10.1016\/j.vaccine.2020.04.067_b0080","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1473-3099(16)30253-5","article-title":"Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data","volume":"16","author":"Sidikou","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0085","unstructured":"Centers for Disease Control and Prevention. Menomune (meningococcal polysaccharide vaccine) discontinuation."},{"key":"10.1016\/j.vaccine.2020.04.067_b0090","unstructured":"Advisory Committee on Immunization Practices. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2013. p. 1\u201322."},{"key":"10.1016\/j.vaccine.2020.04.067_b0095","unstructured":"Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521\u201339."},{"key":"10.1016\/j.vaccine.2020.04.067_b0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.04.067_b0105","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1080\/21645515.2019.1581542","article-title":"Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence","volume":"15","author":"Alderfer","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.04.067_b0110","doi-asserted-by":"crossref","first-page":"7141050","DOI":"10.1155\/2016\/7141050","article-title":"Alternative confidence interval methods used in the diagnostic accuracy studies","volume":"2016","author":"Erdo\u011fan","year":"2016","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.vaccine.2020.04.067_b0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<783::AID-SIM488>3.0.CO;2-2","article-title":"Confidence intervals for the log-normal mean","volume":"16","author":"Zhou","year":"1997","journal-title":"Stat Med."},{"key":"10.1016\/j.vaccine.2020.04.067_b0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2020.04.067_b0125","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.04.067_b0130","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.04.067_b0135","unstructured":"Agency EM. Assessment report for Menveo."},{"key":"10.1016\/j.vaccine.2020.04.067_b0140","unstructured":"Agency EM. Assessment report for Nimenrix."},{"key":"10.1016\/j.vaccine.2020.04.067_b0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2020.04.067_b0150","doi-asserted-by":"crossref","unstructured":"van der Heiden M, Boots AMH, Bonacic Marinovic AA, de Rond LGH, van Maurik M, Tcherniaeva I, et al. Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults. Front Immunol. 2017;8.","DOI":"10.3389\/fimmu.2017.00817"},{"key":"10.1016\/j.vaccine.2020.04.067_b0155","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America","volume":"14","author":"Stamboulian","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0160","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1128\/CVI.00099-14","article-title":"Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom","volume":"21","author":"Ramasamy","year":"2014","journal-title":"Clin Vaccin Immunol"},{"key":"10.1016\/j.vaccine.2020.04.067_b0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2015.07.003","article-title":"Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years","volume":"38","author":"Lalwani","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0170","doi-asserted-by":"crossref","first-page":"015","DOI":"10.1186\/s12879-015-1138-y","article-title":"Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial","volume":"15","author":"Borja-Tabora","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.067_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2020.04.067_b0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.04.067_b0185","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d \u2013 Potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.067_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/14712598.2012.725718","article-title":"Glycoconjugate vaccines","volume":"13","author":"Pace","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2020.04.067_b0195","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1080\/21645515.2018.1452576","article-title":"Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations","volume":"14","author":"Juergens","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.04.067_b0200","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.vaccine.2018.05.046","article-title":"Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study","volume":"36","author":"Dbaibo","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.067_b0205","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:45Z","timestamp":1759401885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20305843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":41,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20305843"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: A Phase III randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}